ICS division to merge with Comprehensive NeuroScience
Innovative Clinical Solutions has entered into a definitive agreementto merge its Clinical Studies subsidiary with a unit of Comprehensive NeuroScience, a privately-held firm that focuses on drugs used to treat neuropsychiatric illnesses.
The merger will result in a new health care research organization with significant expertise in the central nervous system area and combined projected revenue for 2001 of approximately $50 million. The firms said that the combined business will provide "multi-therapeutic, Phase I-IV clinical research services as well as an array of medical information technology services."
It will be the USA's largest CNS-focused clinical trials company, with 34 research sites. While the company's specialty will remain CNS, it will also conduct research in the areas of women's health, endocrinology and pain management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze